Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

Literature DB >> 18176957

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

Eric R Kallwitz¹, Alan McLachlan, Scott J Cotler.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPAR alpha and PPAR gamma to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 18176957 PMCID： PMC2673387 DOI： 10.3748/wjg.14.22

Source DB: PubMed Journal: World J Gastroenterol ISSN： 1007-9327 Impact factor: 5.742

108 in total

1. Functional characterization of a peroxisome proliferator response-element located in the intron 3 of rat peroxisomal thiolase B gene.

Authors: Franck Hansmannel; Marie-Claude Clémencet; Catherine Le Jossic-Corcos; Takashi Osumi; Norbert Latruffe; Valérie Nicolas-Francés
Journal: Biochem Biophys Res Commun Date: 2003-11-07 Impact factor: 3.575

2. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.

Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Craig A Sponseller; Karen Hampton; Bruce R Bacon
Journal: J Hepatol Date: 2003-04 Impact factor: 25.083

3. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors: Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal: Hepatology Date: 2003-04 Impact factor: 17.425

Review 4. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors: Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal: Hepatology Date: 2003-05 Impact factor: 17.425

5. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal: Hepatology Date: 2003-10 Impact factor: 17.425

6. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.

Authors: Asish K Saha; Paco R Avilucea; Ji Ming Ye; Murwarid M Assifi; Edward W Kraegen; Neil B Ruderman
Journal: Biochem Biophys Res Commun Date: 2004-02-06 Impact factor: 3.575

Review 7. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

Authors: D Grahame Hardie
Journal: Endocrinology Date: 2003-09-04 Impact factor: 4.736

8. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

Authors: Mandeep Bajaj; Swangjit Suraamornkul; Thongchai Pratipanawatr; Lou J Hardies; Wilailak Pratipanawatr; Leonard Glass; Eugenio Cersosimo; Yoshinori Miyazaki; Ralph A DeFronzo
Journal: Diabetes Date: 2003-06 Impact factor: 9.461

9. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

Authors: Oksana Gavrilova; Martin Haluzik; Kimihiko Matsusue; Jaime J Cutson; Lisa Johnson; Kelly R Dietz; Christopher J Nicol; Charles Vinson; Frank J Gonzalez; Marc L Reitman
Journal: J Biol Chem Date: 2003-06-11 Impact factor: 5.157

10. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.

Authors: Toshimasa Yamauchi; Junji Kamon; Yusuke Ito; Atsushi Tsuchida; Takehiko Yokomizo; Shunbun Kita; Takuya Sugiyama; Makoto Miyagishi; Kazuo Hara; Masaki Tsunoda; Koji Murakami; Toshiaki Ohteki; Shoko Uchida; Sato Takekawa; Hironori Waki; Nelson H Tsuno; Yoichi Shibata; Yasuo Terauchi; Philippe Froguel; Kazuyuki Tobe; Shigeo Koyasu; Kazunari Taira; Toshio Kitamura; Takao Shimizu; Ryozo Nagai; Takashi Kadowaki
Journal: Nature Date: 2003-06-12 Impact factor: 49.962

44 in total

Review 1. Pharmacological agents for NASH.

Authors: Vlad Ratziu
Journal: Nat Rev Gastroenterol Hepatol Date: 2013-10-15 Impact factor: 46.802

2. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells.

Authors: Wei Cui; Stephen L Chen; Ke-Qin Hu
Journal: Am J Transl Res Date: 2010-01-01 Impact factor: 4.060

3. IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.

Authors: Jue Wei; Min Shi; Wei-Qi Wu; Hui Xu; Ting Wang; Na Wang; Jia-Li Ma; Yu-Gang Wang
Journal: World J Gastroenterol Date: 2011-12-21 Impact factor: 5.742

4. SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver.

Authors: Linhao Li; Haishan Li; Brandy Garzel; Hui Yang; Tatsuya Sueyoshi; Qing Li; Yan Shu; Junran Zhang; Bingfang Hu; Scott Heyward; Timothy Moeller; Wen Xie; Masahiko Negishi; Hongbing Wang
Journal: Mol Pharmacol Date: 2015-01-27 Impact factor: 4.436

5. The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.

Authors: Tereza Ventura-Holman; Abulkhair Mamoon; Maria C Subauste; Jose S Subauste
Journal: Mol Biol Rep Date: 2010-06-23 Impact factor: 2.316

6. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.

Authors: Chuang-Yu Cao; Yu-Yuan Li; Yong-Jian Zhou; Yu-Qiang Nie; Yu-Jui Yvonne Wan
Journal: Tohoku J Exp Med Date: 2012-08 Impact factor: 1.848

7. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.

Authors: James E Nelson; Elizabeth M Brunt; Kris V Kowdley
Journal: Hepatology Date: 2012-09-20 Impact factor: 17.425